Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
Website: https://www.novartis.com/
2125 articles with Novartis
-
The U.S. FDA's Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
-
The data collected from the cut-off demonstrates that patients can maintain an average of 9.6 months without disease progression after the initial dosage of the tislelizumab-chemotherapy treatment.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy's cost-effectiveness.
-
Although the data was preliminary from a Phase Ib trial, investors are already speculating that the drug - when and if it makes it to regulators - could compete with Amgen’s Lumakras (sotorasib).
-
Novartis announced a global restructuring that will include cutting thousands of jobs. The restructuring is intended to effectively merge two divisions within Novartis into one.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
4/6/2022
Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
-
With the accelerated approval from the U.S. Food and Drug Administration, Vijoice becomes the first treatment approved in the United States for PROS
-
Here's a look at the eight most profitable biopharma companies around the world. Profitability, in this case, refers to net income, as opposed to total revenue or sales.
-
As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.
-
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer
3/25/2022
ITM Isotope Technologies Munich SE supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration approved radiotherapeutic, PluvictoTM for the treatment of adult patients with prostate-specific membrane antigen -positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
-
A federal judge in Delaware tossed out a lawsuit by Genentech, Inc., a Roche company, accusing Novartis' Sandoz division of patent infringement.
-
The FDA approved Pluvicto (targeted radioligand therapy) for use in adults with PSMA-positive mCRPC that has already metastasized to other body parts.
-
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
3/23/2022
Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617).
-
Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.
-
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
-
It was a busy week for clinical trial announcements. Here's a look.
-
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
-
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.